Aurobindo Pharma has announced the incorporation of a new wholly-owned subsidiary in Chile, named Aurobindo Pharma Chile SpA. This entity was formed by Helix Healthcare B.V., another wholly-owned subsidiary of Aurobindo. Incorporated on October 7, 2025, the primary goal of this new subsidiary is to expand the company’s pharmaceutical product business within the Chilean market. The initial share capital stands at CLP 1,000,000.
Chilean Expansion
Aurobindo Pharma has officially expanded its global footprint with the incorporation of a new subsidiary, Aurobindo Pharma Chile SpA, in Chile. This strategic move aims to enhance the availability of Aurobindo’s pharmaceutical products within the Chilean market. The new entity is a wholly owned subsidiary.
Subsidiary Details
The newly formed Aurobindo Pharma Chile SpA was incorporated on October 7, 2025, and is a subsidiary of Helix Healthcare B.V., which itself is a wholly owned subsidiary of Aurobindo Pharma. The initial share capital invested in the new subsidiary is CLP 1,000,000, divided into 100 shares with a nominal value of CLP 10,000 each. The signed formation documents were received on October 22, 2025.
Strategic Rationale
This expansion into Chile aligns with Aurobindo Pharma’s broader strategy of increasing its international presence and reach. The establishment of Aurobindo Pharma Chile SpA is expected to facilitate the distribution and sales of a wider range of pharmaceutical products within the Chilean market, contributing to the company’s overall growth objectives.
Source: BSE
